GfK consolidates US operations

Share this article:

Global marketing research giant GfK has announced the consolidation of its US operations into a single entity: GfK Healthcare.

The newly combined company represents the merger of three previously separate operations, GfK Market Measures, GfK Strategic Marketing and GfK V2, and will employ 275 employees across two offices in New Jersey, and one in Pennsylvania.

According to GfK Healthcare CEO Richard Vanderveer, previously group chief executive officer of GfK US Healthcare Companies and chief executive officer of GfK V2, “a few redundancies were encountered [in the consolidation] and were dealt with appropriately.”

Vanderveer credits the decision to manufacturers' declining revenues and profits, and the need for a “flexible framework of resources,” and project requirements that demand close cooperation among the companies.

“The integration, we hope, will attract clients who are looking for marketing research with both breadth and global depth,” said Vanderveer.

Barry Zimmerman, formerly the president of GfK Market Measures, will serve as president and COO. Dan Fitzgerald, former group EVP of GfK US Healthcare Companies, will serve as chief financial officer. Brian Hull, formerly president of GfK Strategic Marketing, will serve as chief consulting officer. Jim Callandrillo, former chief operating officer of GfK Market Measures, will serve as chief research and operations officer, with Maureen McLaughlin, former chief marketing officer of GfK Market Measures, to be chief marketing officer of the new company.

The new entity represents the largest provider of fully integrated custom healthcare marketing research in the US, according to a statement.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...